Novo Nordisk A/S pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs ...

Novo Nordisk narrowed its earnings guidance as intensifying competition, pricing pressure and copycat versions of its ...

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

COPENHAGEN () -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a ...

Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.

In June, Novo ended a partnership with Hims & Hers that provided access to Wegovy through the pharma's Novocare Pharmacy because Hims & Hers was trying to skirt legal restrictions on compounding ...

Leading global healthcare company Novo Nordisk announces the launch of Wegovy® in Hong Kong, now available at private clinics ...